trending Market Intelligence /marketintelligence/en/news-insights/trending/p229ajokef8eowuae6ekcg2 content esgSubNav
In This List

Motif Bio submits application for antibiotic medicine with US FDA

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints

Blog

Shore Capital is Now Available in S&P Global’s Aftermarket Research Collection


Motif Bio submits application for antibiotic medicine with US FDA

Motif Bio PLC submitted an application with the U.S. Food & Drug Administration, seeking approval to market its investigational antibiotic for treating bacterial skin infections.

The New York-based biopharmaceutical company said it submitted a new drug application with the U.S. regulator for iclaprim, which was evaluated in two successful phase 3 trials.

Iclaprim is expected to receive priority review, meaning the U.S. FDA will make a decision on the medicine within six months instead of the standard 10-month review period.

The drug may also be eligible for 10 years of market exclusivity in the U.S.